Two digital pathology scientists from Ventana Medical Systems Inc, Tuscon, Ariz, a member of the Roche Group, will present the latest advancements in digital pathology multiplexing and algorithm-assisted breast cancer testing at the Pathology Visions Conference in Baltimore on October 28 to 31.
Pascal Bamford, PhD, project lead for Ventana multiplex and molecular assays, will present the key concepts of multiplexing gene and protein targets in tissue and discuss the importance and current challenges of translating this technology to the clinical setting. Multiplexing genomic and proteomic targets in formalin-fixed, paraffin-embedded (FFPE) tissue is widely regarded as a key enabling technology in the future of personalized medicine and companion diagnostics.
Watch the video of Bamford’s full comments here.
Gerardo Fernandez, MD, medical director for digital pathology at Ventana will discuss the evolution of automated algorithmic analysis of the standard breast cancer immunohistochemistry (IHC) panel, from the pitfalls of early scoring techniques to the more robust late-generation methods in use today.
Watch the video of Fernandez’s full comments here.